Clinical trial · no report yet · Phase 3

JUPITER-02 trial: what clinicians have said so far

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

NCT03581786 ↗
Completed
Shanghai Junshi Bioscience Co., Ltd.
Deep size, estimated: 301+ verified statements once built

We haven't built an HCP commentary report on JUPITER-02 (toripalimab in recurrent or metastatic nasopharyngeal carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on JUPITER-02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
10 posts on X, typically up to 44 once built
7 YouTube videos, typically up to 31 once built
6 podcast episodes, typically up to 26 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer
Phase: Phase 3
Status: Completed
Conditions: Recurrent or Metastatic NPC
Interventions: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy; Placebos
Arms: placebo combine with chemotherapy · Placebo comparator
TORIPALIMAB INJECTION(JS001 )combine with chemotherapy · Experimental
Enrollment: 289
Primary outcomes: IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Start: Oct 18, 2018
Primary completion: May 30, 2020
Results posted: Yes
Registry record: NCT03581786 · updated Sep 2, 2025

Publications

linked from the registry

Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181. PubMed 38015220
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi YR, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Liu Z, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Feng H, Yao S, Keegan P, Xu RH. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021 Sep;27(9):1536-1543. doi: 10.1038/s41591-021-01444-0. Epub 2021 Aug 2. PubMed 34341578

Get this report

Deep

Report, built on orderBuilt within 24 hours of confirming your order: $1,950

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md